Report of the third meeting on "Influenza vaccines that induce broad spectrum and long-lasting immune responses", World Health Organization, Geneva, Switzerland, 3-4 December 2007

Vaccine

Volumn 26, Issue 20, 2008, Pages 2443-2450

  Girard, Marc P ^a   Osterhaus, Albert ^b   Pervikov, Yuri ^c   Palkonyay, Laszlo ^d   Kieny, Marie Paule ^d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c World Health Organization ^*

^d WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PLACEBO; SECRETORY IMMUNOGLOBULIN;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE IRRITATION; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; SWITZERLAND; VIRUS STRAIN; WORLD HEALTH ORGANIZATION;

ADJUVANTS, IMMUNOLOGIC; HUMANS; INFLUENZA VACCINES; SWITZERLAND; VACCINES, ATTENUATED; VACCINES, INACTIVATED; WORLD HEALTH ORGANIZATION;

EID: 42649138207     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.006     Document Type: Conference Paper

References (30)

1. Cassetti MC, Couch R, Wood J, Pervikov Y. Report of meeting on the development of influenza vaccines with broad spectrum and long-lasting immune responses. World Health Organization, Geneva, Switzerland, 26-27 February 2004. Vaccine 2005;23(13):1529-1533.
2. Hampson AW, Osterhaus AD, Pervikov Y, Kieny MP. Report of the second meeting on the development of influenza vaccines that induce broad-spectrum and long-lasting immune responses. World Health Organization, Geneva, Switzerland, 6-7 December 2005. Vaccine 2006;24(23):4897-4900.
3. Tamura S., Tanimoto T., and Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 58 4 (2005) 195-207
4. Quan F.S., Compans R.W., Nguyen H.H., and Kang S.M. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J Virol 82 3 (2008) 1350-1359
5. Bessa J., Schmitz N., Hinton H.J., Schwarz K., Jegerlehner A., and Bachmann M.F. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol 38 1 (2008) 114-126
6. Quan F.S., Huang C., Compans R.W., and Kang S.M. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 81 7 (2007) 3514-3524
7. Atmar R.L., Keitel W.A., Cate T.R., Munoz F.M., Ruben F., and Couch R.B. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine 25 29 (2007) 5367-5373
8. Song J.H., Nguyen H.H., Cuburu N., Horimoto T., Ko S.Y., Park S.H., et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci USA (2008)
9. Cuburu N., Kweon M.N., Song J.H., Hervouet C., Luci C., Sun J.B., et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 25 51 (2007) 8598-8610
10. Auewarakul P., Kositanont U., Sornsathapornkul P., Tothong P., Kanyok R., and Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 25 4 (2007) 659-663
11. Belshe R.B., Newman F.K., Cannon J., Duane C., Treanor J., Van Hoecke C., et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 351 22 (2004) 2286-2294
12. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., and Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351 22 (2004) 2295-2301
13. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 13 (2006) 1343-1351
14. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 9523 (2006) 1657-1664
15. Nicholson K.G., Colegate A.E., Podda A., Stephenson I., Wood J., Ypma E., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 357 9272 (2001) 1937-1943
16. Stephenson I., Bugarini R., Nicholson K.G., Podda A., Wood J.M., Zambon M.C., et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 191 8 (2005) 1210-1215
17. Leroux-Roels I., Borkowski A., Vanwolleghem T., Drame M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 9587 (2007) 580-589
18. Agger E.M., Rosenkrands I., Olsen A.W., Hatch G., Williams A., Kritsch C., et al. Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. Vaccine 24 26 (2006) 5452-5460
19. Halloran M.E., Longini Jr. I.M., Gaglani M.J., Piedra P.A., Chu H., Herschler G.B., et al. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol 158 4 (2003) 305-311
20. Gaglani M.J., Piedra P.A., Herschler G.B., Griffith M.E., Kozinetz C.A., Riggs M.W., et al. Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch Pediatr Adolesc Med 158 1 (2004) 65-73
21. Piedra P.A., Gaglani M.J., Kozinetz C.A., Herschler G., Riggs M., Griffith M., et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine 23 13 (2005) 1540-1548
22. Halloran M.E., Piedra P.A., Longini Jr. I.M., Gaglani M.J., Schmotzer B., Fewlass C., et al. Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004. Vaccine 25 20 (2007) 4038-4045
23. Piedra P.A., Gaglani M.J., Kozinetz C.A., Herschler G.B., Fewlass C., Harvey D., et al. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics 120 3 (2007) e553-e564
24. Ghendon Y.Z., Kaira A.N., and Elshina G.A. The effect of mass influenza immunization in children on the morbidity of the unvaccinated elderly. Epidemiol Infect 134 1 (2006) 71-78
25. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356 7 (2007) 685-696
26. Tam J.S., Capeding M.R., Lum L.C., Chotpitayasunondh T., Jiang Z., Huang L.M., et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 26 7 (2007) 619-628
27. Baskin C.R., Bielefeldt-Ohmann H., Garcia-Sastre A., Tumpey T.M., Van Hoeven N., Carter V.S., et al. Functional genomic and serological analysis of the protective immune response resulting from vaccination of macaques with an NS1-truncated influenza virus. J Virol 81 21 (2007) 11817-11827
28. De Filette M., Min Jou W., Birkett A., Lyons K., Schultz B., Tonkyro A., et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 337 1 (2005) 149-161
29. Bright R.A., Carter D.M., Daniluk S., Toapanta F.R., Ahmad A., Gavrilov V., et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25 19 (2007) 3871-3878
30. Ge J., Deng G., Wen Z., Tian G., Wang Y., Shi J., et al. Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J Virol 81 1 (2007) 150-158